Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

347 results about "Molecular imaging" patented technology

Molecular imaging originated from the field of radiopharmacology due to the need to better understand fundamental molecular pathways inside organisms in a noninvasive manner.

Federated Distributed Computational Graph Platform for Oncological Therapy and Biological Systems Analysis

A federated distributed computational system enables secure biological data analysis and genomic medicine with enhanced oncological therapy capabilities. The system implements patient-specific tumor-on-a-chip analysis through microfluidic control systems and cellular heterogeneity preservation, while integrating fluorescence-enhanced diagnostics using CRISPR-LNP targeting and robotic surgical navigation. The architecture coordinates spatiotemporal analysis of gene therapy delivery through molecular imaging and immune response tracking, and implements bridge RNA integration with multi-target synchronization. Treatment selection is optimized through multi-criteria scoring and patient-specific simulation modeling. Each federated node contains a local processing unit for biological data analysis, privacy preservation protocols, and a hierarchical knowledge graph structure. The system implements cross-species genetic analysis, environmental response modeling, and multi-scale tensor-based data integration, enabling research institutions to collaborate on complex, large-scale biological analyses while maintaining strict data privacy controls.
Owner:QOMPLX INC

Dimer labelled precursors targeting cxcr4 receptor and radiotracers derived therefrom

The invention relates to the technical field of molecular imaging probes, in particular to a CXCR4 receptor targeting dimer labeling precursor and a radioactive tracer derived from the same. Compared with [68Ga] Ga-SDNUM01, the radioactive tracer agent [68Ga] Ga-SDNUM04 derived from the targeted CXCR4 receptor dimer labeled precursor provided by the invention has the advantages that the retention time of the radioactive tracer agent [68Ga] Ga-SDNUM04 in tumors is longer, and the radioactive tracer agent [68Ga] Ga-SDNUM04 can also show an excellent imaging effect within 45 minutes.
Owner:SHANDONG UNIV

System and Method for Early Identification of Difficult Venous Access of a Patient

A system and method for determining a difficult venous access of a patient. Logic processes meta data acquired by a vasculature assessment device coupled with the patient. The meta data, e.g., vessel diameter, vessel depth, vessel wall thickness, vessel wall elasticity, tissue elasticity, tissue profusion, blood flow rate, or hydration level. The logic further determines a difficult venous access by performing an algorithm on the meta data. The algorithm is defined utilizing machine learning techniques applied to an ongoing collection data sets acquired from a plurality of systems across a plurality of patients undergoing catheter insertion events. The data set may also include patient data such as weight, age, etc. The vasculature assessment device may include ultrasound imaging, infrared imaging, molecular imaging, Raman spectroscopy, or optical coherence tomography to acquire one or both of three-dimensional imaging data and the meta data.
Owner:BARD ACCESS SYSTEMS INC

Probe precursor and probe for targeting CXCR4 receptor as well as preparation method and application of probe

The invention relates to the field of radiopharmaceutical labeling, in particular to a probe precursor and a probe for targeting a CXCR4 receptor as well as a preparation method and application of the probe. After the probe precursor for targeting the CXCR4 receptor provided by the invention is combined with radionuclide, the CXCR4 receptor can be accurately positioned in vivo, the in-vivo targeting performance is excellent, and the purpose of tumor molecular imaging is achieved through nuclear medicine imaging. The structural formula of the probe precursor for targeting the CXCR4 receptor is as shown in the formula (I): # imgabs0 # formula (I).
Owner:SHANDONG UNIV

Sugar nucleic acid molecule image probe as well as preparation method and use method thereof

ActiveCN119139500Aprecision retouchingModification controllableRadioactive preparation carriersCancers diagnosisA-DNA
The present invention relates to a molecular imaging probe for tumor diagnosis, and provides a sugar nucleic acid molecular imaging probe, the probe comprises a DNA aptamer sequence and more than one glycosyl nucleoside module, and is labeled by radionuclide, the DNA aptamer sequence can specifically target tumor cells after functional folding; the glycosyl nucleoside module is a glycosyl modified nucleoside derivative, is accurately modified at the 5'end or / and the 3 'end of the aptamer through DNA solid-phase synthesis, has the imaging characteristics of biological safety, high sensitivity and high resolution, and has an excellent diagnosis effect on part of cancers which are difficult to diagnose by a traditional method. The invention also provides a preparation method and a use method of the sugar nucleic acid molecular imaging probe, so that sugar modification of the aptamer is convenient, rapid, accurate, controllable and modularized, and the sugar nucleic acid molecular imaging probe has huge clinical application potential and transformation value in cancer diagnosis.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Tandem ratio response Raman probe as well as preparation method and application thereof

The invention belongs to the technical field of molecular imaging, and particularly relates to a tandem ratio response Raman probe as well as a preparation method and application thereof. The Raman probe disclosed by the invention is a substance consisting of a gold nano substrate, dye molecules and a polymer, the gold nano substrate is good in chemical stability, rich in surface plasmon and capable of enhancing Raman signals; raman reporter molecules are connected to the surface of the substance, serial response of ROS and pH can be achieved, meanwhile, a raman peak which is basically unchanged serves as an internal reference, response peaks of the two markers and an internal reference raman spectrum peak are not overlapped, and accurate quantification of ROS and pH can be achieved. The reporter molecule has pH stability when the ROS does not respond, and can realize pH fluctuation monitoring after the ROS is started. According to the present invention, the neuroinflammation site in the brain microenvironment can be imaged, the pH fluctuation in the brain disease environment can be specifically imaged, the pH monitoring of the lesion site can be easily achieved, and the important significance can be provided for the deep understanding of the brain function change and the disease progress mechanism.
Owner:GUANGDONG HONG KONG MACAO GREATER BAY AREA PRECISION MEDICINE RESEARCH INSTITUTE (GUANGZHOU) +1

Nanometer delivery device for gastric cancer targeted drug and use method of nanometer delivery device

The invention discloses a nanometer delivery device for a gastric cancer targeted drug and a use method of the nanometer delivery device, and belongs to the technical field of drug targeted delivery. The device comprises a molecular recognition and optimization module which is responsible for accurately recognizing a tumor cell specific molecular marker and providing personalized treatment strategy recommendation; the nano-carrier design module is used for designing multifunctional lipid-polymer hybrid nano-particles and carrying out surface targeting ligand modification; the intelligent drug loading module is used for improving the stability and controllability of drug loading based on a pH / temperature sensitive release mechanism and effectively reducing the toxic influence of non-targeted tissues; the molecular imaging and monitoring module integrates a nanoprobe imaging technology and a quantum dot tracing technology, constructs a treatment-imaging integrated system, realizes real-time dynamic monitoring of a treatment process, and provides instant feedback of a molecular level; and the risk assessment module is used for establishing a safety database and providing dynamic risk assessment of the treatment process through a biological safety assessment system and long-term tracking management.
Owner:SHAANXI CANCER HOSPITAL (SHAANXI INST OF CANCER PREVENTION & TREATMENT) (SHAANXI THIRD PEOPLES HOSPITAL)

Molecular imaging probe for diagnosing lung cancer and preparation method thereof

ActiveCN119144608ARealize non-invasive visual detectionImprove stabilitySugar derivativesX-ray constrast preparationsAptamerCancer cell
The invention belongs to the field of molecular imaging probes for cancer diagnosis, and discloses a targeted nucleic acid aptamer aiming at tumor-associated calcium channel sensing protein 2, a molecular imaging probe for diagnosing lung cancer and a preparation method of the molecular imaging probe. The nucleic acid aptamer contains 46 nucleotides, can specifically target the surface Trop-2 of a lung cancer tumor cell, has a specific targeting recognition effect with Trop-2 overexpressed lung cancer cells such as non-small cell lung cancer cells H1650 and small cell lung cancer cells SBC-2, and can be used for molecular imaging of Trop-2 positive lung cancer patients. The molecular imaging probe can be used for noninvasive visual molecular imaging of lung cancer, and has the advantages of high specificity, high sensitivity, good imaging effect and the like. The preparation method of the molecular imaging probe is simple in reaction condition, low in cost and easy for clinical transformation.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Ai-driven motion correction of pet data

Systems and methods include acquisition of an anatomical image of an object, acquisition of molecular imaging data of the object at the plurality of photon detectors, reconstruction of a functional image based on the molecular imaging data, input of the anatomical image and the functional image to a trained neural network to generate a second functional image, and presentation of the second functional image.
Owner:SIEMENS MEDICAL SOLUTIONS USA INC

Molecular probe targeting GPC3 and application

PendingCN119499408Agood stability in vitroClear developmentAntibody ingredientsRadioactive preparation carriersAntibody fragmentsMolecular imaging
The invention relates to the field of molecular imaging, in particular to a molecular probe targeting GPC3. The invention claims to protect a molecular probe targeting GPC3, the molecular probe is a compound having the following sequence, or a pharmaceutically acceptable salt or ester thereof: (GPC3 antibody, including antibody fragment of GPC3 antibody, or single domain antibody thereof) m-Rn, where R is selected from a linking group, a chelating agent, a radionuclide, another targeting polypeptide or monoclonal antibody, monoclonal antibody fragment, single domain antibody, and Rn is selected from a linking group, a chelating agent, a radionuclide, another targeting polypeptide or monoclonal antibody, a monoclonal antibody fragment, and a single domain antibody. And a group consisting of small molecule inhibitors; wherein n represents the number of R, and n is equal to 0-4; wherein m is not 0. The probe has good in-vitro stability, can be clearly developed in tumors, and has good specificity.
Owner:WUHAN RAYDIF BIOTECHNOLOGY CO LTD +1

Preparation method and application of CD70 specific nano antibody molecular imaging probe

The invention provides a preparation method and application of a CD70 specific nano antibody molecular imaging probe. The probe comprises a tumor targeting group, radionuclide and a bifunctional chelating agent, the tumor targeting group is a CD70 specific nano antibody; the CD70 specific nano antibody is R8B4, and the amino acid sequence of the R8B4 is as shown in SEQ ID No. 1. The probe provided by the invention can realize noninvasive diagnosis of solid tumors such as renal clear cell carcinoma and malignant tumors of a blood system; reabsorption of the compound in the kidney is effectively inhibited through charge adjustment, kidney uptake is remarkably reduced, non-specific signals are reduced, the signal-to-noise ratio during targeted imaging or treatment is increased, and the imaging quality and treatment safety are improved. The probe not only has a wide application prospect in tumor diagnosis, but also provides a new technical support for targeted therapy and individualized precision medical treatment, and has important scientific research and clinical application values.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Computer assisted molecular imaging methods and systems

A method for molecular image acquisition includes beginning acquisition of a molecular image via a molecular imaging system, performing one or more analyses of the molecular image during acquisition of the molecular image to determine whether at least one hot spot is present in the image, and if it is determined that it is statistically significant that there is either at least one hot spot present or there is not at least one hot spot present in the image in any one of the one or more analyses of the molecular image, performing at least one of providing a recommendation that the acquisition be stopped or stopping the acquisition automatically.
Owner:SMART BREAST CORP

Preparation method and application of radionuclide-labeled Trop2-specific single-domain antibody probe

The present invention relates to the field of molecular imaging, nuclear medicine and single-domain antibody technology for tumor diagnosis and treatment, and in particular to a method for preparing a radionuclide-labeled Trop2-specific single-domain antibody probe and its application. The Trop2-specific single-domain antibody has a CDR1 having an amino acid sequence shown in SEQ ID No.1, a CDR2 having an amino acid sequence shown in SEQ ID No.2, and a CDR3 having an amino acid sequence shown in SEQ ID No.3. The Trop2-specific single-domain antibody prepared by the present invention 18 The F-labeled single-domain antibody probe is used for immuno-PET imaging, which realizes the non-invasive visualization of Trop2 in vivo and further realizes the non-invasive diagnosis of Trop2-positive tumors. The probe has the advantages of simple preparation process, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and easy clinical transformation.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

A CD47-specific molecular imaging probe and its preparation method and application

The present invention discloses a CD47-specific molecular imaging probe and its preparation method and application, which relates to the molecular imaging, nuclear medicine and nano-antibody technology fields of tumor diagnosis and treatment, including human CD47-specific monovalent nano-antibody probes and human CD47-specific nano-antibody fusion protein probes; its preparation method comprises: modifying CD47-specific nano-antibody C2 by compounds, synthesizing radionuclide labeling precursors, and preparing the CD47-specific molecular imaging probe by radionuclide labeling; the prepared probe is applied to immune PET imaging and radioimmunotherapy of malignant tumors. The present invention has the advantages of simple preparation process, low cost, high specificity, high stability, and easy clinical transformation. It can realize non-invasive visualization of heterogeneous expression of CD47, screen patients with high expression of CD47, and further carry out CD47-specific radioimmunotherapy, that is, realize integrated diagnosis and treatment.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Adaptation of pet data acquisition parameters

Systems and methods include determination of an anatomical image of an object, input of the anatomical image to a trained neural network to generate a synthetic functional image, acquisition of molecular imaging data of the object based on acquisition parameters, reconstruction of a functional image based on the molecular imaging data, determination of a difference between the functional image and the synthetic functional image, change of one of the acquisition parameters based on the difference, acquisition of second molecular imaging data of the object based on the changed acquisition parameters, and reconstruction of a second functional image based on the second molecular imaging data.
Owner:SIEMENS MEDICAL SOLUTIONS USA INC

Atherosclerosis model based on nano-molecule magnetic resonance imaging and machine learning algorithm, nano-targeting probe and application

The invention belongs to the technical field of biological medicine and electronic information technology, and discloses an atherosclerosis model based on nano-molecule magnetic resonance imaging and a machine learning algorithm, a nano-targeting probe and application of the atherosclerosis model based on the nano-molecule magnetic resonance imaging and the machine learning algorithm. A high-resolution MRI image capable of specifically displaying foam macrophage distribution in the plaque is obtained; then, image omics features are extracted from the images, a machine learning model which is constructed based on the features and verified by pathological labels is adopted for analysis, and finally an objective and quantitative plaque vulnerability score is output. According to the model disclosed by the invention, an objective and quantitative risk score can be output by fusing nano-targeted molecular imaging and machine learning, and accurate and reliable quantification of plaque vulnerability is realized. According to the invention, through systematic integration of targeted molecular imaging and machine learning, significant technical progress is brought.
Owner:THE SECOND HOSPITAL OF TIANJIN MEDICAL UNIV

3D semiconductor detector system

A detector system for molecular imaging of a radionuclide comprises a 3D semiconductor detector comprising a plurality of sensor stacks of sensors made of a semiconductor material having an average atomic number Z below 40. A read-out circuitry connected to the pixels is configured to output, for each interaction induced by an incident gamma ray in the detector, a signal representative of a time, a position and an energy of the interaction in the detector. The interactions in the detector belonging to a same event induced by the incident gamma ray are predicted based on the output signals and used to estimate a direction of the incident gamma ray and reconstruct an image based on the estimated directions of incident gamma rays.
Owner:SISNAP AB

Tumor targeting reagent and application thereof in tumor diagnosis

The invention discloses a tumor targeting reagent and application thereof in tumor diagnosis. The targeting reagent has strong affinity to tumors, strong specificity and no biotoxicity, is relatively stable in vivo, and can be used as a molecular probe to be applied to molecular imaging and / or treatment of various integrin alpha6 high-expression tumors; the targeting reagent provided by the invention comprises the tumor targeting peptide RWYDeA, and further comprises a radionuclide chelating agent, other connecting structures and a hydroxyl substitution structure, and the structure is beneficial to improving the tumor targeting property of the targeting reagent, prolonging the tumor binding time and achieving a better tumor diagnosis effect; the method can be used for preparing products for diagnosing / treating diseases related to high expression of integrin alpha6.
Owner:GUANGZHOU GENBIONOVA MEDICAL TECH CO LTD

Oxidase response type molecular probe as well as preparation method and application thereof

The invention relates to an oxidase response type molecular probe as well as a preparation method and application thereof, and belongs to the technical field of medical imaging. Aiming at the problem that the inflammation activity is difficult to accurately evaluate in the prior art, the invention provides a molecular imaging probe capable of responding to the activity of in-vivo myeloperoxidase (MPO), and the molecular imaging probe can be used for real-time and non-invasive imaging monitoring of the activity of the in-vivo MPO, so that the activity of the inflammatory reaction of a focus is accurately evaluated. The invention provides a chelating agent with structural characteristics of a chelating unit and an enzyme response unit, and is characterized in that the enzyme response molecular probe is constructed by taking rigid framework cyclohexanediamine (CDTA) as a transition metal chelating unit and taking electron-rich functional groups (such as phenol, catechol or 5-hydroxytryptamine) as the enzyme response unit. The probe is chelated with paramagnetic metal (such as Mn < 2 + >) for magnetic resonance imaging (MRI) or radioactive metal (such as 68Ga) for positron emission tomography (PET), so that specific response to MPO activity is realized. The dynamic stability of the probe is remarkably improved; after the MPO is responded, the relaxation efficiency is improved by 2-3 times, and the sensitivity is optimized; the cytotoxicity is low; in an acute pancreatitis model, the MRI contrast noise ratio (delta CNR) reaches 77.39 + / -7.04 and is 4.2 times that of a control group, the PET uptake rate is remarkably improved, bimodal imaging is supported, and accurate positioning and quantitative evaluation of the inflammation activity are achieved.
Owner:NORTH SICHUAN MEDICAL COLLEGE

A clinically-translatable ROS / RNS molecular imaging agent using a radiolabeled derivative of edaravone (EDV)

The present disclosure relates to compounds, pharmaceutical compositions, and methods of using the compounds and compositions to image reactive oxygen and nitrogen species (RONS). The disclosed compounds and pharmaceutical compositions can also be useful in treating diseases or disorders due to oxidative stress or otherwise based on RONS pathophysiology such as, for example, neurological diseases, cancer, cardiovascular diseases, and ischemia reperfusion injury (IRI). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +2

Living blood vessel and lymph multi-parameter quantitative photoacoustic microscopic imaging system

The invention discloses a living blood vessel and lymph multi-parameter quantitative photoacoustic microscopic imaging system which comprises a high repetition frequency laser source, a photoacoustic scanning probe and a molecular imaging device. Through the cooperation of the multi-wavelength fast switching laser and the high-speed scanning probe, synchronous, dynamic and quantitative imaging of vascular function parameters and lymph concentration in a living tissue microenvironment is realized. The system has a video-level imaging rate and can capture a rapid biological process; through coaxial design of dispersion correction and a photoacoustic focus, high spatial resolution and high signal-to-noise ratio of a multispectral image are guaranteed; and the compact probe design realizes large-range scanning. The technology provides a powerful in-vivo visualization tool for research on life science problems such as tumor evolution and drug metabolism.
Owner:FUDAN UNIVERSITY

PD-L1 targeting compound, radioactive tracer agent and preparation method and application of PD-L1 targeting compound and radioactive tracer agent

The invention is suitable for the technical field of biological medicine and nuclear medicine, and provides a PD-L1 targeting compound, a radioactive tracer agent and a preparation method and application of the PD-L1 targeting compound and the radioactive tracer agent. The radioactive tracer provided by the invention has strong binding force with PD-L1, can accurately locate PD-L1 in vivo, has excellent in-vivo targeting performance, and can achieve the purpose of tumor molecular imaging through nuclear medicine imaging; meanwhile, noninvasive visualization of PD-L1 expression is achieved, non-invasive tumor diagnosis can be effectively completed through small animal PET / CT verification, and the clinical application prospect is wide; in addition, the PD-L1 targeting compound and the radioactive tracer derived from the PD-L1 targeting compound further have the advantages of being simple in preparation process, low in cost, high in specificity, good in in-vivo and in-vitro stability, long in imaging period, easy to clinically convert and the like, and the comprehensive performance is outstanding.
Owner:JILIN UNIVERSITY

Targeting CDK4 / 6 molecular imaging probe labeling precursor, probe and preparation method and application of targeting CDK4 / 6 molecular imaging probe labeling precursor

The invention relates to the technical field of medicinal chemistry, radiopharmaceutical chemistry and clinical nuclear medicine, in particular to a CDK4 / 6-targeted molecular imaging probe labeling precursor, a probe and a preparation method and application thereof. According to the molecular imaging probe [68Ga] Ga-PY03 provided by the invention, on the basis of a Ribociclib structure, a PEG1 chain and proline with envelope conformation are introduced, so that a hydrophobic region in a protein binding pocket can be filled, Van der Waals force can be enhanced, the molecular imaging probe [68Ga] Ga-PY03 can be stably bound with CDK4 / 6, and the targeting of the molecular imaging probe to the CDK4 / 6 is further ensured; the hydrophilicity of the molecular imaging probe can be adjusted, and kidney uptake is reduced; and the compound has excellent tumor / liver and tumor / muscle ratio, and can effectively improve tumor uptake.
Owner:SHANDONG UNIV

Compound targeting DDR1 receptor and radioactive tracer agent derived from compound

The invention relates to the technical field of radiopharmaceutical labeling, in particular to a compound targeting a DDR1 receptor and a radioactive tracer derived from the compound. According to the present invention, the radioactive tracer agent generated after the mixing reaction of the DDR1 receptor targeting compound and the radionuclide has strong receptor binding force with the DDR1 receptor, can accurately position the DDR1 receptor in vivo, has excellent in-vivo targeting performance, and can achieve the tumor molecular imaging purpose through nuclear medicine imaging. The invention relates to a DDR1 receptor targeting compound, which has a structural formula as shown in a formula (I): # imgabs0 # formula (I).
Owner:SHANDONG UNIV

Mama fluorescence tomography system based on pixel-region three-way scanning

The invention relates to the technical field of optical molecular imaging, in particular to a fluorescent molecular tomography three-dimensional reconstruction system, method and device based on pixel and region integration layering Mama (PR3SM) and a three-dimensional scanning (Tri-scan) mechanism. Aiming at the problems of how to effectively capture global and local spatial characteristics of a fluorescence signal, how to accurately model a radial aggregation and diffusion mode of a fluorescence probe and how to realize a self-adaptive loss function to improve the reconstruction precision, the invention provides a layered three-way scanning Mama fluorescence molecular tomography reconstruction system based on pixel-region integration. The reconstruction precision is improved by introducing a Mama model, the feature modeling capability is enhanced by combining a layered PR-Mama module with a pixel-level SSM and a region-level SSM, forward, backward and spiral center scanning modes are fused through a three-way scanning mechanism, and a fluorophore distribution mode is effectively captured; the adaptive structure senses the loss function, integrates the mean square error and the local structure similarity loss, and improves the adaptability of the loss function.
Owner:SHANXI UNIV

EGFR (epidermal growth factor receptor) targeting peptide, fluorescent probe, composition and application

The invention belongs to the technical field of targeting peptides, and particularly relates to an EGFR targeting peptide, a fluorescent probe, a composition and application. The targeting peptide has an amino acid sequence as shown in SEQ ID NO: 1. Through verification, the targeting peptide has the capability of selective enrichment in tumor cells, and is beneficial to tumor recognition and treatment. The fluorescent probe coupled by the targeting peptide and the ICG fluorescent dye can specifically recognize and target an EGFR receptor, realizes effective aggregation and retention at a tumor part, is suitable for targeted diagnosis and treatment of tumors, can realize accurate imaging, has important clinical transformation potential, and becomes a molecular imaging probe with application prospects.
Owner:YANTAI NEW DRUG DEV SHANDONG PROVINCIAL LAB

Organometallic gold(III) complexes for radiolabeling biomolecules for applications in positron emission tomography (PET) molecular imaging

The 18F-labeling of unprotected peptides and sugars via thioarylation using a Au(III)-[˜F]fluoroaryl complex is reported. The chemoselective method generates 18F-labeled S-aryl bioconjugates in an aqueous environment in 15 min with high radiochemical yields and displays excellent functional group tolerance. This approach utilizes an air and moisture stable, robust organometallic Au(III) complex and highlights the versatility of designer organometallic reagents as efficient agents for rapid radiolabeling.
Owner:RGT UNIV OF CALIFORNIA

Nectin-4 targeted aptamer nuclide diagnosis and treatment integrated probe

The invention discloses a Nectin-4 targeted nucleic acid aptamer nuclide diagnosis and treatment integrated probe, and relates to the field of biotechnology and diagnosis and treatment integration and treatment, and the diagnosis and treatment integrated probe comprises a Nectin-4 targeted nucleic acid aptamer, a nuclide chelating ligand and a nuclide for marking; wherein the Nectin-4 targeting nucleic acid aptamer has a base sequence as shown in any one of SEQ ID NO.1-3, or has a base sequence of which the homology with the base sequence as shown in any one of SEQ ID NO.1-3 is more than 80%. The diagnosis and treatment integrated probe prepared by the invention can be applied to PET / CT diagnosis and internal irradiation radioactive therapy, on one hand, non-invasive visual molecular imaging of Nectin-4 receptor protein overexpression tumors is realized, and on the other hand, radioactive therapy of malignant bladder cancer is further realized; the probe is good in specific targeting effect and high in tumor uptake and has a diagnosis and treatment integrated function.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Dimer-labeled precursor targeting CXCR4 receptor and radioactive tracer derived therefrom

The present invention relates to the technical field of molecular imaging probes, and in particular to a dimer-labeled precursor targeting CXCR4 receptor and a radioactive tracer derived therefrom. 68 Ga]Ga-SDNUM01, a radioactive tracer derived from a precursor labeled for targeting CXCR4 receptor dimer provided by the present invention [ 68 Ga]Ga‑SDNUM04 remained in the tumor for a longer time and showed excellent imaging effect even at 45 minutes.
Owner:SHANDONG UNIV